46,412 Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.4% during the third quarter, HoldingsChannel.com reports. The fund owned 398,121 shares of the medical equipment provider’s stock after selling 46,412 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Zimmer Biomet were worth $35,365,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $1,344,282,000. Primecap Management Co. CA acquired a new stake in Zimmer Biomet during the 2nd quarter worth $328,578,000. Bank of America Corp DE acquired a new stake in Zimmer Biomet during the 2nd quarter worth $187,480,000. Equity Investment Corp acquired a new stake in Zimmer Biomet during the 2nd quarter worth $144,748,000. Finally, Legal & General Group Plc acquired a new stake in Zimmer Biomet during the 2nd quarter worth $126,167,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $107.08 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $112.54. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.94. The business has a 50 day simple moving average of $95.01 and a 200-day simple moving average of $91.99. The stock has a market capitalization of $20.42 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 2.65 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the company earned $1.90 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet’s third-quarter sales of $2.063 billion and adjusted EPS of $1.90 topped analyst estimates. The company also raised its full-year 2026 outlook; hip and S.E.T. sales helped offset softer knee results. Third-quarter results
• Positive Sentiment: Analysts raised targets, with UBS moving to $130 and keeping a Buy rating, and RBC increasing its target to $125 with an Outperform rating. These revisions signal improved expectations for the shares. UBS analyst rating
• Neutral Sentiment: JPMorgan, Citi, and Wells Fargo also lifted their price targets, but retained Neutral or Equal Weight ratings. Bernstein raised its target to $107 while maintaining Market Perform, reflecting a more cautious view.
• Negative Sentiment: Knee-market challenges and margin pressure temper the results. Reported diluted EPS fell 13.8% year over year to $1.00, although adjusted EPS was flat at $1.90, so investors may weigh the outlook improvement against operating pressures. Quarterly outlook and knee-market challenges

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Truist Financial set a $114.00 target price on shares of Zimmer Biomet in a research note on Thursday. Barclays raised Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Finally, Stifel Nicolaus set a $125.00 price target on Zimmer Biomet in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $111.95.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.